Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PSEUDO-12 vs AFRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
FDA: Temporary relief of nasal congestion due to colds, allergies, or sinusitis,Off-label: Adjunct in otitis media, eustachian tube dysfunction
Temporary relief of nasal congestion due to colds, hay fever, or other upper respiratory allergies.
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
Hepatic metabolism via N-demethylation (CYP3A4) and glucuronidation; minor renal excretion as unchanged drug.
Primarily hepatic metabolism via oxidative deamination and glucuronidation; the major enzyme involved is monoamine oxidase (MAO).
Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
Binding: 30-40%; primarily to albumin.
80–90% bound to serum albumin and alpha-1-acid glycoprotein.
Vd: 2.6-3.5 L/kg; indicates extensive tissue distribution (e.g., lungs, liver, kidney).
4.0–5.0 L/kg. Indicates extensive tissue distribution, with concentrations exceeding plasma levels in lung, liver, kidney, and brain.
Oral: 90-100% (immediate-release); 80-90% (extended-release).
Oral: 40–50% (first-pass metabolism). Intranasal: 70–80% (systemic absorption variable). Intravenous: 100%.
e GFR 30-50 m L/min: 30 mg every 6 hours as needed; maximum 120 mg/day. e GFR <30 m L/min: 30 mg every 12 hours as needed; maximum 60 mg/day.
Cr Cl 30-50 m L/min: prolong interval to every 18-24 hours; Cr Cl <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: 30 mg every 6 hours as needed; maximum 120 mg/day. Child-Pugh C: use is not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: avoid use.
Children 6-12 years: 30 mg orally every 4-6 hours; maximum 120 mg/day. Children 12-17 years: same as adult dosing.
Children 6-12 years: 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; maximum 1 tablet per day. Children <6 years: not recommended.
Initiate at 30 mg every 6 hours as needed; maximum 120 mg/day due to increased sensitivity and higher risk of adverse effects.
Start with 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; monitor for CNS effects, anticholinergic side effects, and hypertension.
None.
None.
Cardiovascular effects: hypertension, palpitations, arrhythmias; CNS stimulation: insomnia, anxiety, tremor; exacerbation of glaucoma, hyperthyroidism, diabetes; urinary retention in prostatic hypertrophy; rebound congestion with prolonged use.
Hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, increased intraocular pressure, prostatic hyperplasia; use caution in elderly patients; do not exceed recommended dosage.
Severe hypertension, coronary artery disease, concurrent MAO inhibitor therapy, narrow-angle glaucoma, urinary retention, hypersensitivity to sympathomimetics.
Hypersensitivity to any component; concurrent use or recent use (within 14 days) of MAO inhibitors; severe hypertension or coronary artery disease.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) if taking MAOIs concurrently. Limit caffeine-containing beverages as they may increase CNS stimulation.
Avoid excessive caffeine intake as it may increase stimulant effects. No significant food interactions known.
FDA Pregnancy Category C. First trimester: no evidence of structural teratogenicity in human studies but avoid due to potential vasoconstriction. Second/third trimester: risk of fetal tachycardia, decreased placental perfusion, and potential for maternal hypertension; prolonged use may cause fetal hypoxia.
Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsistent. Second and third trimesters: Avoid due to risk of uterine vasoconstriction and potential fetal hypoxia, especially near term. Overall, FDA Pregnancy Category C.
Excreted into breast milk in low amounts (M/P ratio ~0.5). Considered safe at recommended doses; however, monitor infant for irritability or insomnia.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio approximately 2.6–3.5). Use with caution as it can reduce milk production and may cause irritability in the infant. A single dose is likely safe, but chronic use is not recommended.
No specific dose adjustment required; however, use lowest effective dose for shortest duration due to physiologic changes (increased renal clearance may slightly reduce plasma levels).
No specific dose adjustments are established for pregnancy. However, due to increased plasma volume and renal clearance, the duration of action may be shorter. Use the lowest effective dose for the shortest duration, typically 60 mg every 4–6 hours (max 240 mg/day).
Pseudoephedrine is a sympathomimetic amine used as a decongestant. It is contraindicated in severe hypertension, coronary artery disease, and concurrent MAOI use. Monitor for CNS stimulation, insomnia, and elevated blood pressure. Extended-release formulations should not be crushed or chewed.
AFRINOL contains oxymetazoline, an imidazoline sympathomimetic with alpha-adrenergic agonist activity. It causes vasoconstriction in nasal mucosa. Limit use to 3 days to avoid rhinitis medicamentosa. Avoid in patients with narrow-angle glaucoma, severe hypertension, or MAOI use. Onset is within minutes, duration up to 12 hours.
Do not use if you have high blood pressure or heart disease unless directed by a doctor.,Avoid taking within 4 hours of bedtime to prevent insomnia.,Do not crush or chew extended-release tablets.,Limit caffeine intake while taking this medication.,Stop use and consult a doctor if symptoms persist after 7 days.
Do not use for more than 3 consecutive days to avoid rebound congestion.,Do not share the bottle with others to prevent infection.,Do not exceed recommended dosage; use only 2-3 sprays per nostril every 10-12 hours as directed.,Avoid using if you have high blood pressure, heart disease, or glaucoma without consulting a doctor.,Consult a doctor if symptoms persist beyond 3 days or if you experience severe side effects like headache, rapid heartbeat, or dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PSEUDO-12 vs AFRINOL, answered by our medical review team.
PSEUDO-12 is a Decongestant that works by Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.. AFRINOL is a Decongestant that works by Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PSEUDO-12 and AFRINOL depend on the specific clinical indication. These are both Decongestant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PSEUDO-12 is: 60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.. The standard adult dose of AFRINOL is: Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PSEUDO-12 and AFRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PSEUDO-12 is classified as Category C. FDA Pregnancy Category C. First trimester: no evidence of structural teratogenicity in human studies but avoid due to potential vasoconstriction. Second/third trimester: risk of fe. AFRINOL is classified as Category C. Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsist. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.